Takeuchi K, Hase S, Mizoguchi H, Komoike Y, Tanaka A
Department of Pharmacology and Experimental Therapeutics, Kyoto Pharmaceutical University, Misasagi, Yamashina, Kyoto 607-8414, Japan.
J Physiol Paris. 2001 Jan-Dec;95(1-6):51-7. doi: 10.1016/s0928-4257(01)00009-2.
Most of non-steroidal anti-inflammatory drugs (NSAIDs) except aspirin (ASA) produce intestinal damage in rats. In the present study, we re-examined the intestinal toxic effect of ASA in rats, in comparison with various NSAIDs, and investigated why ASA does not cause damage in the small intestine, in relation to its metabolite salicylic acid (SA). Various NSAIDs (indomethacin; 10 mg/kg; flurbiprofen; 20 mg/kg; naproxen; 40 mg/kg; dicrofenac; 40 mg/kg; ASA; 20-200 mg/kg) were administered s.c., and the small intestinal mucosa was examined macroscopically 24 h later. All NSAIDs tested, except ASA, caused hemorrhagic lesions in the small intestine, with a decrease of mucosal PGE(2) contents. ASA did not provoke any damage, despite inhibiting (prostaglandin) PG production, and prevented the occurrence of intestinal lesions induced by indomethacin, in a dose-related manner. This protective action of ASA was mimicked by the equimolar doses of SA (17.8-178 mg/kg). Indomethacin caused intestinal hypermotility, in preceding to the occurrence of lesion, and this event was followed by increases of enterobacterial translocation in the mucosa. Both ASA and SA prevented both the intestinal hypermotility and the bacterial translocation seen after indomethacin treatment. In addition, the protective effect of SA was not significantly influenced by either the adenosine deaminase or the adenosine receptor antagonists. Following administration of ASA, the blood SA levels reached a peak within 30 min and remained elevated for more than 7 h. These results suggest that SA has a cytoprotective action against indomethacin-induced small intestinal lesions, and this action may be associated with inhibition of the intestinal hypermotility and the bacterial translocation, but not mediated by endogenous adenosine. Failure of ASA to induce intestinal damage may be explained, at least partly, by a protective action of SA, the metabolite of ASA.
除阿司匹林(ASA)外,大多数非甾体抗炎药(NSAIDs)在大鼠中会造成肠道损伤。在本研究中,我们重新研究了ASA对大鼠的肠道毒性作用,并与多种NSAIDs进行比较,同时探讨了ASA与其代谢产物水杨酸(SA)相关的为何不会导致小肠损伤的原因。将各种NSAIDs(吲哚美辛;10mg/kg;氟比洛芬;20mg/kg;萘普生;40mg/kg;双氯芬酸;40mg/kg;ASA;20 - 200mg/kg)皮下注射给药,24小时后对小肠黏膜进行宏观检查。除ASA外,所有测试的NSAIDs均导致小肠出现出血性病变,同时黏膜前列腺素E2(PGE2)含量降低。尽管ASA抑制了(前列腺素)PG的产生,但并未引发任何损伤,并且以剂量相关的方式预防了吲哚美辛诱导的肠道病变的发生。ASA的这种保护作用可被等摩尔剂量的SA(17.8 - 178mg/kg)模拟。在病变发生之前,吲哚美辛会导致肠道运动亢进,随后黏膜中的肠细菌移位增加。ASA和SA均可预防吲哚美辛治疗后出现的肠道运动亢进和细菌移位。此外,SA的保护作用不受腺苷脱氨酶或腺苷受体拮抗剂的显著影响。给予ASA后,血液中SA水平在30分钟内达到峰值,并持续升高超过7小时。这些结果表明,SA对吲哚美辛诱导的小肠病变具有细胞保护作用,并且这种作用可能与抑制肠道运动亢进和细菌移位有关,但不是由内源性腺苷介导的。ASA未能诱导肠道损伤至少部分可以通过其代谢产物SA的保护作用来解释。